I was a fan of Pfizer (PFE)
early in 2012, and the stock delivered good returns as it beat the
S&P 500. At this new, higher, price level it is a little harder to
have quite the same affection for the company. I do have respect for how
the company has streamlined - cutting costs, selling the nutrition
business to Nestle, and preparing for the spin-off of Zoetis. I also
think there are some worthwhile drugs both in the pipeline and early
launch phases. All that said, it's hard to be as excited about the
stock's value today, and I wonder if it's time for another large-scale
move to better position the company for long-term growth.
Click here to continue:
Pfizer Needs To Reload
No comments:
Post a Comment